Krystal Biotech, Inc. (KRYS) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 35 days, typically, give or take 5 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Mon, Nov 2, 2026before open 33 8-K
Q2 FY2026Mon, Aug 3, 2026before open 34 8-K
Q4 FY2025Tue, Feb 17, 2026before open 48 8-K
Q3 FY2025Mon, Nov 3, 2025before open 34 8-K
Q2 FY2025Mon, Aug 4, 2025before open 35 8-K
Q1 FY2025Tue, May 6, 2025before open 36 8-K
Q3 FY2024Mon, Nov 4, 2024before open 35 8-K
Q2 FY2024Mon, Aug 5, 2024before open 36 8-K

What they guided beta

Q3 FY2026 "Pricing negotiations are now complete in both Germany and Italy, and the Company expects to launch VYJUVEK in Italy in early 2027." exhibit
Q3 FY2026 "Pricing negotiations are ongoing in multiple European countries and the United Kingdom, with decisions expected in Spain later this year, and in France no earlier than 2027." exhibit
Q3 FY2026 "The Company expects to meet with the FDA in the first quarter of 2027, following completion of scale validation, to discuss study results, the scale, and study designs to enable a registrational study start in 2027." exhibit
Q3 FY2026 "The Company now expects the last patient visit in February 2027 with top-line results reported shortly thereafter." exhibit
Q3 FY2026 "The Company now expects to complete enrollment of approximately 60 patients in EMERALD-1 and report top-line results in 2027." exhibit
Q2 FY2026 "Pricing discussions with German and French reimbursement authorities remain ongoing and are expected to continue until at least 2H 2026 in Germany and into 2027 in France." exhibit
Q2 FY2026 "The Company expects to file multiple additional marketing authorization applications for VYJUVEK in 2H 2026, including in Switzerland and Australia." exhibit
Q2 FY2026 "The Company will share the design and associated statistical analysis of the registrational study following alignment with the FDA, which is expected in 4Q 2026, and is on track to initiate the registrational study in 2027." exhibit
Q2 FY2026 "The Company expects to report interim study results in 2027." exhibit
Q2 FY2026 "The Company expects to meet with the FDA following the completion of HALITE-1 to discuss study results, the scale, and study designs to enable a registrational study start in 2027." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/KRYS
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/KRYS

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

KRYS earnings date badge

HTML

<a href="https://veritasdata.dev/company/KRYS/"><img src="https://veritasdata.dev/embed/KRYS.svg" alt="KRYS earnings date" width="240" height="56"></a>

Markdown

[![KRYS earnings date](https://veritasdata.dev/embed/KRYS.svg)](https://veritasdata.dev/company/KRYS/)

Script

<script async src="https://veritasdata.dev/embed/KRYS.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/KRYS"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.